Meningococcal group A, C, Y and W-135 conjugate vaccine

被引：0

作者：

Lee H. Harrison

Nitin Mohan

Peter Kirkpatrick

机构：

[1] Lee H. Harrison is at the Infectious Diseases Epidemiology Research Unit,

[2] University of Pittsburgh Graduate School of Public Health and School of Medicine,undefined

[3] Pittsburgh,undefined

[4] Pennsylvania 15101,undefined

[5] USA. lharriso@edc.pitt.edu,undefined

[6] Nitin Mohan is at IMS Health Americas,undefined

[7] Toronto,undefined

[8] Canada. NMohan@ca.imshealth.com,undefined

[9] Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,undefined

来源：

Nature Reviews Drug Discovery | 2010年 / 9卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11–55 years.

引用

页码：429 / 430

页数：1

共 50 条

[1] Meningococcal group A, C, Y and W-135 conjugate vaccine
Harrison, Lee H.
Mohan, Nitin
Kirkpatrick, Peter
[J]. NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (06) : 429 - 430
[2] Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease
Hedari, Carine P.
Khinkarly, Rima W.
Dbaibo, Ghassan S.
[J]. INFECTION AND DRUG RESISTANCE, 2014, 7 : 85 - 99
[3] Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines
Pace, David
Pollard, Andrew J.
[J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2007, 92 (10) : 909 - 915
[4] Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults
Bermal, Nancy
Huang, Li-Min
Dubey, A. P.
Jain, Hermant
Bavdekar, Ashish
Lin, Tzou-Yien
Bianco, Veronique
Baine, Yaela
Miller, Jacqueline M.
[J]. HUMAN VACCINES, 2011, 7 (02): : 239 - 247
[5] Meningococcal A, C, W135 and Y conjugate vaccine
不详
[J]. AUSTRALIAN PRESCRIBER, 2011, 34 (01) : 30 - 30
[6] TETRAVALENT (A, C, Y, W-135) MENINGOCOCCAL VACCINE IN CHILDREN - IMMUNOGENICITY AND SAFETY
CADOZ, M
ARMAND, J
ARMINJON, F
GIRE, R
LAFAIX, C
[J]. VACCINE, 1985, 3 (03) : 340 - 342
[7] ost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents
Si, Si
Zomer, Ella
Fletcher, Samantha
Lee, Jenny
Liew, Danny
[J]. VACCINE, 2019, 37 (35) : 5009 - 5015
[8] Menveo®: a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y
Cooper, Brian
DeTora, Lisa
Stoddard, Jeffrey
[J]. EXPERT REVIEW OF VACCINES, 2011, 10 (01) : 21 - 33
[9] Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135
Keyserling, Harry L.
Pollard, Andrew J.
DeTora, Lisa M.
Gilmet, Gregory P.
[J]. EXPERT REVIEW OF VACCINES, 2006, 5 (04) : 445 - 459
[10] Meningococcal vaccine groups A C Y W-135 conjugateGuillain Barre syndrome: case report
[J]. Reactions Weekly, 2007, 1135 (1) : 22 - 22

← 1 2 3 4 5 →